Premium
Lansoprazole triple therapy for Helicobacter pylori —is 5 days enough?
Author(s) -
O'Connor Hj,
Ramona McLoughlin,
Sean G. Kelly,
J Laundon,
K. Cunnane
Publication year - 1998
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1998.00290.x
Subject(s) - lansoprazole , medicine , regimen , helicobacter pylori , clarithromycin , metronidazole , gastroenterology , adverse effect , rapid urease test , proton pump inhibitor , surgery , gastritis , antibiotics , microbiology and biotechnology , biology
Background: Seven‐day proton pump inhibitor triple therapy is currently the treatment of choice for Helicobacter pylori infection. It is unclear whether triple therapy for less than 7 days might preserve efficacy while at the same time improving patient acceptability and compliance. Aim: To evaluate the Helicobactericidal efficacy, ulcer healing capacity and patient acceptability of a 5‐day lansoprazole‐based triple therapy regimen. Methods: Sixty‐nine consecutive patients with H. pylori ‐positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days. Ulcer healing medication was not continued after the 5‐day regimen. H. pylori status was assessed before and at least 4 weeks after therapy by rapid urease test and histology. Adverse events and compliance were assessed by direct questioning. Results: All 69 patients attended for repeat endoscopy and 63 were H. pylori ‐negative after therapy giving a cure rate of 91% (95% Cl: 85–98%). Of the 59 patients with active ulcers, 58 were healed at repeat endoscopy giving an ulcer healing rate of 98% (95% Cl: 92–100%). All patients fully complied with therapy and mild adverse events, mainly gastrointestinal, were reported by 11 patients (16%). Conclusions: Five‐day lansoprazole triple therapy is an effective regimen for H. pylori infection which combines a high cure rate and ulcer healing efficacy with the advantages of excellent patient acceptability and compliance.